Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


With Generous Partner Abbott Back For More, Reata Aims High Again

This article was originally published in Start Up

Executive Summary

Texas biotech Reata can add another $400 million license deal, its second with Abbott, to the $178 million it has raised from venture backers. But this time it's for preclinical assets.

You may also be interested in...

The Abbott Split Up: Who Wins?

After implementing a major workforce reduction in January, Abbott Laboratories re-organized its diversified company into three units – proprietary pharmaceuticals, durable growth products and innovation-driven devices. Its latest announcement cements that change: Abbott will divide into a diversified medical products company.

Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes

Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.

Reata Sets Sights On 2012 Bardoxolone Launch With $78 Million Financing In Hand

Funding will allow Reata to complete the second of two pivotal trials for its lead product candidate in development for advanced chronic kidney disease.

Related Content

Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts